Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XILLIX FDA APPROVED -- Ignore unavailable to you. Want to Upgrade?

To: Robert Dydo who wrote (355)	2/3/1999 6:30:00 PM
From: Edward W. Richmond	Read Replies (1) \| Respond to of 572

Robert, at the AGM, Pierre Leduc was pretty clear that Miravant was the photodynamic therapy company of choice for Xillix to team up with. I think he took some heat about QLT, both being in Vancouver. My spin on the matter is that XLX was dead broke and the Miravant deal injected the much-needed cash into the company. As a long-term holder of both XLX and QLT, I don't see too much positive for XLX from the Miravant deal. QLT will be first to market by a mile in macular degeneration which is the massive market that would quickly embrace such a treatment. The penetration of QLT in treating cancer has been very disappointing and isn't improving very quickly. I hope I'm wrong as I don't see Olympus as being a great marketer for XLX products. Regards, Ed